Alzamend Neuro financials
$1.82+5.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 30 | Q3 '26 Jan 31 | Q2 '26 Oct 31 | Q1 '26 Jul 31 | Q4 '25 Apr 30 | Q3 '25 Jan 31 | Q2 '25 Oct 31 | Q1 '25 Jul 31 | Q4 '24 Apr 30 | Q3 '24 Jan 31 | Q2 '24 Oct 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.0M | -$2.9M | -$2.2M | -$998.1K | -$2.7M | -$1.1M | -$1.0M | -$1.4M | -$962.4K | -$850.1K | -$2.7M | -$2.9M |
| Net income | -$3.0M | -$2.9M | -$2.2M | -$1.0M | -$2.7M | -$1.6M | -$1.1M | -$1.4M | -$974.4K | -$851.5K | -$2.7M | -$2.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.68 | $-0.71 | $-0.58 | $-0.30 | $-1.28 | — | $-1.75 | $-3.60 | $-11.42 | — | $-33.93 | $-39.87 |
| EBITDA | -$3.0M | -$2.8M | -$2.2M | -$970.4K | -$2.7M | -$1.1M | -$1.0M | -$1.4M | -$949.7K | -$837.4K | -$2.6M | -$2.9M |
| Operating cash flow | -$1.1M | -$2.8M | -$1.7M | -$1.2M | -$2.4M | -$688.7K | -$1.4M | -$3.4M | -$1.1M | -$1.4M | -$2.0M | -$1.5M |
| Free cash flow | -$1.1M | -$2.8M | -$1.7M | -$1.2M | -$2.4M | -$898.7K | -$1.4M | -$3.4M | -$1.1M | -$1.4M | -$2.0M | -$1.5M |
| Diluted shares | 4.5M | 4.1M | 3.8M | 3.4M | 2.1M | — | 0.6M | 0.4M | 0.1M | — | 0.1M | 0.1M |
Balance sheet
| Period end | Jul 31 | Apr 30 | Jan 31 | Oct 31 | Jul 31 | Apr 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.6M | $710.7K | $2.7M | $4.4M | $5.6M | $3.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $8.5M | $2.1M | $4.0M | $5.1M | $6.3M | $4.6M |
| Total liabilities | $2.7M | $1.3M | $1.9M | $717.5K | $983.3K | $634.8K |
| Shareholders' equity | $5.8M | $733.2K | $2.2M | $4.4M | $5.3M | $4.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology